Q4 EARNINGS: Covidien looking good as Medtronic takeover nears
This article was originally published in Clinica
Executive Summary
Covidien finished its fiscal 2014 strongly, with fourth-quarter sales of $2.73bn up 7% year-on-year and above analyst consensus of $2.69bn. Meanwhile, adjusted diluted earnings were $1.15 per share, compared with analyst predictions of $1.02 per share and $0.91 per share in Q4 2013.